Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the
liver of people with chronic hepatitis B. The main questions it aims to answer are:
- how well is it working in the liver
- how does Imdusiran affect the hepatitis B virus
Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total
of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran,
and the second 8 weeks after the last dose of Imdusiran.